Studies of the biogenic amine transporters. VII. Characterization of a novel cocaine binding site identified with [125I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate

Synapse

Volumn 28, Issue 4, 1998, Pages 322-338

  Rothman, Richard B ^a   Silverthorn, Mayme L ^a   Glowa, John R ^b   Matecka, Dorota ^b   Rice, Kenner C ^b   Carroll, F Ivy ^c   Partilla, John S ^a   Uhl, George R ^a   Vandenbergh, David J ^a   Dersch, Christina M ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Benztropine; Bupropion; Cocaine; Dopamine; GBR12909; GBR12935; Mazindol; Nomifensine; Transmitter uptake inhibitors neuronal

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; IODINE 125; SEROTONIN TRANSPORTER;

ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CAUDATE NUCLEUS; GUINEA PIG; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIGAND BINDING; MEMBRANE TRANSPORT; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEPTOR AFFINITY; SPECIES DIFFERENCE;

ANIMALS; BINDING SITES; CARRIER PROTEINS; CAUDATE NUCLEUS; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; GUINEA PIGS; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MEMBRANES; NERVE TISSUE PROTEINS; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 6844236997     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199804)28:4<322::AID-SYN8>3.0.CO;2-B     Document Type: Article

References (92)

1. 3H]Cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: Allosteric modulation by paroxetine. Neurochem. Res., 17:1275-1283.
2. Akunne, H.C., Dersch, C.M., Cadet, J.L., Baumann, M.H. Char, G.U. Partilla, J.S., de Costa, B.R., Rice, K.C., Carroll, F.I., and Rothman, R.B. (1994) Studies of the biogenic amine transporters. III. Demonstration of two binding sites for [3H]GBR12935 and [3H]BTCP in rat caudate membranes. J. Pharmacol. & Exp. Ther., 268:1462-1475.
3. 3H]1-[1-(2-thienyl)cyclohexyl]piperidine labels two high affinity binding sites in human cortex: Further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse, 8:289-300.
4. Batki, S.L. (1990) Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis. West. J. Med., 152:547-552.
5. Benowitz, N.L. (1993) Clinical pharmacology and toxicology of cocaine. Pharmacol. Toxicol., 72:3-12; (erratum 72(6):343).
6. Berger, P., Gawin, F., and Kosten, T.R. (1989) Treatment of cocaine abuse with mazindol (letter). Lancet, 1:283.
7. Bergman, J., Madras, B.K., Johnson, S.E., and Spealman, R.D. (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther., 251:150-155.
8. Bhargava, H.N., Ramarao, P., and Gulati, A. (1988) Effect of methimazole-induced hypothyroidism on multiple opioid receptors in rat brain regions. Pharmacology, 37:356-364.
9. 125I]RTI-55: a potent ligand for dopamine transporters. Eur. J. Pharmacol., 194:133-134.
10. Boja, J.W., Markham, L., Patel, A., Uhl, G., and Kuhar, M.J. (1992a) Expression of a single dopamine transporter cDNA can confer two cocaine binding sites. Neuroscience/NeuroReport, 3: 247-248.
11. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse, 12:27-36.
12. Boja, J.W., Cadet, J.L., Kopajtic, T.A., Lever, J., Seltzman, H.H., Wyrick, C.D., Lewin, A.H., Abraham, P., and Carroll, F.I. (1995) Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester. Mol. Pharmacol., 47:779-786.
13. Bylund, D.B., and Yamamura, H.I. Methods for receptor binding. In: Methods in Neurotransmitter Receptor Analysis. Yamamura, H.I., (ed.). New York: Raven Press, 1990, pp. 1-35.
14. Carroll, F.I., Gao, Y.G., Rahman, M.A., Abraham, P., Parham, K., Lewin, A.H., Boja, J.W., and Kuhar, M.J. (1991) Synthesis, ligand binding, QSAR, and CoMFA study of 3β-(p-substituted phenyl)tropane-2β-carboxylic acid methyl esters. J. Med. Chem., 34:2719-2727.
15. Carroll, F.I., Abraham, P., Lewin, A.H., Parham, K.A., Boja, J.W., and Kuhar, M.J. (1992) Isopropyl and phenyl esters of 3β-(4-substituted phenyl)tropan-2β-carboxylic acids. Potent and selective compounds for the dopamine transporter. J. Med. Chem., 35:2497-2500.
16. Dackis, C.A., and Gold, M.S. (1985) Pharmacological approaches to cocaine addiction. J. Subst. Abuse Treat., 2:139-145.
17. Dackis, C.A., Gold, M.S., and Pottash, A.L. (1986) Central stimulant abuse: Neurochemistry and pharmacotherapy. Adv. Alcohol. Subst. Abuse, 6:7-21.
18. Dackis, C.A., Gold, M.S., Sweeney, D.R., Byron, J.P. Jr., and Climko, R. (1987) Single-dose bromocriptine reverses cocaine craving. Psychiatry Res., 20:261-264.
19. Das, G. (1993a) Cocaine abuse in North America: A milestone in history. J. Clin. Pharmacol., 33:296-310.
20. Das, G. (1993b) Cardiovascular effects of cocaine abuse. Int. J. Clin. Pharmacol., Ther. Toxicol., 31:521-528.
21. 3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains. Neurochem Res., 19:201-208.
22. Di Chiara, G., and Imperato, A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA, 85:5274-5278.
23. Diakogiannis, I.A., Steinberg, M., and Kosten, T.R. (1991) Mazindol treatment of cocaine abuse. A double-blind investigation. NIDA Res. Monogr., 105:514.
24. Freud, S. (1884) Uber Coca. Zentralbl Gesammte Ther., 2:289-314.
25. Gawin, F.H., and Kleber, H.D. (1986) Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch. Gen. Psychiatry, 43:107-113.
26. Golwyn, D.H. (1988) Cocaine abuse treated with phenelzine. Int. J. Addict., 23:897-905.
27. 3H]1-[1-(2-thienyl)cyclohexyl]piperidine binding site (PCP site 2) of guinea pig brain. Synapse, 16:59-65.
28. Guardabasso, V., Munson, P.J., and Rodbard, D. (1988) A versatile method for simultaneous analysis of families of curves. FASEB J., 2:209-215.
29. He, X., Raymon, L.P., Mattson, M.V., Eldefrawi, M.E., and de Costa, B.R. (1993a) Further studies of the structure-activity relationships of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine. Synthesis and evaluation of 1-(2-benzo[b]thienyl)-N,N-dialkylcyclohexylamines at dopamine uptake and phencyclidine binding sites. J. Med. Chem., 36:4075-4081.
30. He, X.S., Raymon, L.P., Mattson, M.V., Eldefrawi, M.E., and de Costa, B.R. (1993b) Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamineuptake and phencyclidine- and sigma-binding sites. J. Med. Chem., 36:1188-1193.
31. Hyttel, J. (1982) Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuropsychopharmacol. Biol. Psychiat., 6:277-295.
32. Hyttel, J., and Larsen, J.J. (1985) Neurochemical profile of LU 19-005. A potent inhibitor of uptake of dopamine, noradrenaline and serotonin. J. Neurochem., 44:1615-1620.
33. Innis, R.B. (1992) Neuroreceptor imaging with SPECT. J. Clin. Psychiat., 53(11):29-34.
34. 3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol., 26:35-44.
35. Knott, G.D., and Reece, D.K. (1972) MLAB: A civilized curve fitting system. Proc. Online 1972 Int. Conf., 1:497-526.
36. Kosten, T.R., and Kleber, H.D. (1988) Differential diagnosis of psychiatric comorbidity in substance abusers. J. Subst. Abuse Treat., 5:201-206.
37. Kosten, T.R., Schumann, B., and Wright, D. (1988) Bromocriptine treatment of cocaine abuse in patients maintained on methadone [letter]. Am. J. Psych., 145:381-382.
38. Kosten, T.R., Morgan, C.M., Falcione, J., and Schottenfeld, R.S. (1992) Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry, 49:894-898.
39. Kuhar, M.J., Ritz, M.C., and Boja, J.W. (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends. Neurosci., 14:299-302.
40. Latkin, C.A., and Mandell, W. (1993) Depression as an antecedent of frequency of intravenous drug use in an urban, nontreatment sample. Int. J. Addict., 28:1601-1612.
41. Liu, Q.-R., Mandiyan, S., Nelson, H., and Nelson, N. (1992) A family of genes encoding neurotransmitter transporters. Proc. Natl. Acad. Sci. USA, 89:6639-6643.
42. Liu, Q.-R., Mandiyan, S., Lopez-Corcuera, B., Nelson, H., and Nelson, N. (1993) A rat brain cDNA encoding a neurotransmitter trnasporter with an unusual structure. FEBS Lett., 315:114-118.
43. Lowry, O.H., Rosenbrough, N.H., Farr, A.L., and Randall, P.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193:265-275.
44. 3H]Cocaine binding sites in caudateputamen. J. Pharmacol. Exp. Ther., 251:131-141.
45. 3H]paroxetine binding in rat brain. J. Neurochem., 50:1783-1790.
46. Margolin, A., Kosten, T., Petrakis, I., and Avants, S.K. (1991) An open pilot study of bupropion and psychotherapy for the treatment of cocaine abuse in methadone-maintained patients. NIDA Res. Monogr., 105:367-368.
47. Marzuk, P.M., Tardiff, K., Leon, A.C., Stajic, M., Morgan, E.B., and Mann, J.J. (1992) Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am. J. Psychiatry, 149:371-375.
48. Matecka, D., Rice, K.C., Rothman, R.B., de Costa, B.R., Glowa, J.R., Wojnicki, F.H.E., Pert, A., George, C., Carroll, F.I., Silverthorn, M.L., Dersch, C.M., Becketts, K.M., and Partilla, J.S. (1995) Synthesis and absolute configuration of chiral piperazines related to GBR 12909 as dopamine reuptake inhibitors. Med. Chem. Res., 5:43-53.
49. Matecka, D., Rothman, R.B., Radesca, L., de Costa, B.R., Dersch, C.M., Partilla, J.S., Pert, A., Glowa, J.R., Wojnicki, F.H.E., and Rice, K.C. (1996) Development of novel, potent and selective dopamine reuptake inhibitors through alteration of the piperazine ring of GBR 12935 and GBR 12909. J. Med. Chem. 39(24): 4704-4716.
50. McGonigle, P., Neve, K.A., and Molinoff, P.B. (1986)A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes. Mol. Pharmacol., 30:329-337.
51. Miller, N.S. (1994) Prevalence and treatment models for addiction in psychiatric populations. Psychiatr. Ann., 24:399-406.
52. Montoya, I.D., Preston, K.L., Cone, E.J., Rothman, R.B., and Gorelick, D.A. (1995) Safety and efficacy of bupropion in combination with bromocriptine for treatment of cocaine dependence. NIDA Res. Monogr. 153:304.
53. Musto, D.F. (1992) Cocaine's history, especially the American experience. Ciba Foundation Symposium, 166:7-14.
54. Nicolaysen, L.C., Pan, H.T., and Justice, J.B. Jr. (1988) Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res., 456:317-323.
55. Ohuoha, D.C., Maxwell, J.W., Cadet, J.L., and Rothman, R.B. (1994) Effect of dopamine receptor antagonists on cocaine-induced subjective effects: A naturalistic case study. NIDA Res. Monogr., 141:442.
56. Pitts, D.K., and Marwah, J. (1987) Neuropharmacology of cocaine: Role of monoaminergic systems. Monogr. Neural Sci., 13:34-54.
57. Post, R.M. (1975) Cocaine psychoses: A continuum model. Am. J. Psych., 132:225-231.
58. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., and Goodwin, F.K. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. JAMA, 264:2511-2518.
59. Resnick, R.B., and Resnick, E. (1986) Psychological issues in the treatment of cocaine abuse. NIDA Res. Monogr., 67:290-294.
60. Ritz, M.C., Lamb, R.J., Goldberg, S.R., and Kuhar, M.J. (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 237:1219-1223.
61. Ritz, M.C., Kuhar, M.J., and George, F.R. (1992) Molecular mechanisms associated with cocaine effects. Possible relationships with effects of ethanol. Recent Dev. Alcohol., 10:273-302.
62. Rodbard, D., Lenox, R.H., Wray, H.L., and Ramseth, D. (1976) Statistical characterization of the random errors in the radioimmunoassay dose-response variable. Clin. Chem., 22:350-358.
63. Ross, S.B., and Renyi, A.L. (1967) Inhibition of the uptake of tritiated catecholamines by anti-depressants and related compounds. Eur. J. Pharmacol., 2:181-186.
64. Rothman, R.B. (1983) Analysis of binding surfaces: A methodology appropriate for the investigation of complex receptor mechanisms and multiple neurotransmitter receptors. Neuropeptides, 4: 41-44.
65. Rothman, R.B. (1986) Binding surface analysis: An intuitive yet quantitative method for the design and analysis of ligand binding studies. Alcohol Drug Res., 6:309-325.
66. Rothman, R.B., and Glowa, J.R. (1995) A review of the effects of dopaminergic agents on humans, animals and drug seeking behavior, and its implications for medication development: Focus on GBR12909. Mol. Neurobiol., 11:1-19.
67. Rothman, R.B., Mele, A., Reid, A.A., Akunne, H.C., Greig, N., Thurkauf, A., de Costa, B.R., Rice, K.C., and Pert, A. (1991a) GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol. Biochem. Behav., 40:387-397.
68. 3H]1,3-Di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: Evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by ¶ ligands. Mol. Pharmacol., 39:222-232.
69. Rothman, R.B., Lewis, B., Dersch, C.M., Xu, H., Radesca, L., de Costa, B.R., Rice, K.C., Kilburn, R.B., Akunne, H.C., and Pert, A. (1993) Identification of a GBR12935 homolog, LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. Synapse, 14:34-39.
70. 125I]RTI-55. J. Pharmacol. Exp. Ther., 270:296-309.
71. Rothman, R.B., Gendron, T.M., and Hitzig, P. (1994b) Combined use of fenfluramine and phentermine in the treatment of cocaine addiction: A pilot case series. J. Subst. Abuse Treat., 11:273-275.
72. 125I]RTI-55, in membranes prepared from whole rat brain minus caudate. J. Pharmacol. Exp. Ther., 274:385-395.
73. Rounsaville, B.J., Anton, S.F., Carroll, K., Budde, D., Prusoff, B.A., and Gawin, F. (1991) Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch. Gen. Psychiatry, 48:43-51.
74. Rovati, G.E., Rodbard, D., and Munson, P.J. (1990) DESIGN: Computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. II. Simultaneous analysis of homologous and heterologous competition curves and analysis blocking and of "multiligand" dose-response surfaces. Anal. Biochem., 184:172-183.
75. 123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse, 11:134-139.
76. Schweri, M.M., Jacobson, A.E., Lessor, R.A., and Rice, K.C. (1987) Metaphit irreversibly inhibits [3H]threo-(+/-)-methylphenidate binding to rat striatal tissue. J. Neurochem., 48:102-105.
77. Schweri, M.M., Thurkauf, A., Mattson, M.V., and Rice, K.C. (1992) Fourphit: A selective probe for the methylphenidate binding site on the dopamine transporter. J. Pharmacol. Exp. Ther., 261:936-942.
78. Sershen, H., Berger, P., Jacobson, A.E., Rice, K.C., and Reith, M.E. (1988) Metaphit prevents locomotor activation induced by various psychostimulants and interferes with the dopaminergic system in mice. Neuropharmacology, 27:23-30.
79. Shimada, S., Kitayama, S., Lin, C.-L., Patel, A., Nanthakumar, E., Gregor, P., Kuhar, M., and Uhl, G. (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science, 254:576-578.
80. 125I]RTI-55 associated with the 5-HT transporter in rat brain membranes. J. Pharmacol. Exp. Ther., 273:213-222.
81. Spealman, R.D., Madras, B.K., and Bergman, J. (1989) Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J. Pharmacol. Exp. Ther., 251:142-149.
82. 125I]RTI-55: In vitro binding and autoradiographic characterization. J. Neurochem., 62:549-556.
83. Stimson, G. (1992) Drug injecting and HIV infection: New directions for social science research. Int. J. Addict., 27:147-163.
84. 3H]Nisoxetine: A radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmacol. Exp. Ther., 260:427-436.
85. Thompson, D.F. (1992) Amantadine in the treatment of cocaine withdrawal. Ann. Pharmacother., 26:933-934.
86. Uhl, G.R., Kitayama, S., Gregor, P., Nanthakumar, E., Persico, A., and Shimada, S. (1992) Neurotransmitter transporter family cDNAs in a rat midbrain library: 'Orphan transporters' suggest sizable structural variations. Brain Res. Mol. Brain Res., 16:353-359.
87. Van der Zee, P., Koger, H.S., Gootjes, J., and Hespe, W. (1980) Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem., 15:363-370.
88. Vandenbergh, D.J., Persico, A.M., and Uhl, G.R. (1992) A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic Taq1 RFLPs. Mol. Brain Res., 15:161-166.
89. 3H]BTCP): A new phencyclidine analog selective for the dopamine uptake complex. Eur. J. Pharmacol., 148:427-436.
90. Weddington, W.W. Jr., Brown, B.S., Haertzen, C.A., Hess, J.M., Mahaffey, J.R., Kolar, A.F., and Jaffe, J.H. (1991) Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am. J. Drug Alcohol Abuse, 17:137-152.
91. Wise, R.A. Brain dopamine and reward. In: Theory in Psychopharmacology. Cooper, S.J. (ed.) London/NY: Academic Press, 1981, pp. 103-122.
92. Wolfsohn, R., and Angrist, B. (1990) A pilot trial of levodopa/ carbidopa in early cocaine abstinence (letter). J. Clin. Psychopharmacol., 10:440-442.